جستجوی مقالات مرتبط با کلیدواژه "انکوژن ها" در نشریات گروه "پزشکی"

In recent years, an increasing trend in the incidence of acute lymphoblastic leukemia (ALL) has been reported. However, the molecular mechanisms involved are not fully understood. Because of the importance of c-MYC in ALL pathogenesis, it is important to consider the associated lncRNAs in identifying the molecular mechanisms involved in disease progression. The consequences of notch signals, depending on the dose and content can be highly pleiotropic. In hemolymphoid, notch signaling affects various cell lines at different stages of growth. The present study aimed to investigate the role of the MYC gene and related LncRNAs as a potential target for the treatment of acute lymphoblastic leukemia.

This case-control study was performed on 40 ALL patients and 40 healthy controls during the years 2020-2021. For this purpose, total RNA was extracted from blood samples and after cDNA synthesis, MYC, and-myc-2-34 dup1 expression was measured using Real-Time PCR. Statistical analysis of the results was performed using SPSS software and appropriate tests.

The results of the gene expression study showed that in patients with ALL, MYC expression and related lncRNA lnc-myc-2-34 dup1 compared to controls had significant increases. These expression changes were not significantly different in age, sex, MRD, and T-ALL and B-ALL categories. lncRNA lnc-myc-2-34 dup1 correlated with the MYC gene, and the ROC curve indicated their potential as a strong biomarker.

Using lncRNAs as diagnostic, prognostic, and therapeutic markers can be an appropriate option that needs further research. According to the present study findings, the increased expression of myc-2-34 dup1 in patients with ALL has been reported for the first time thus, can be used as strong biomarkers.

Tropomyosin receptor kinase B (TRK B) is one of the oncogene agents. The aim of this study was to design and optimize inhibitory peptides for TRK B in U266 cell line. This study was conducted in Qazvin University of Medical Sciences during 2012. After generating the peptides library using sequence tolerance method and optimizing energy of peptides employing backrub protocol in Rosetta 3. 3 software package، the most stable peptides were selected based on the energy scores in R package. Prediction of the three-dimensional structure of the peptides was performed using the molecular dynamic simulation. Peptides-TRK B docking was evaluated by HADDOCK web server. The most stable peptides were designed and their cytotoxicity effects on U266 cells were investigated by the MTT assay. The designed peptides were stable in terms of energy and structure and had high affinity for binding to TRK B. For measuring cell survival during 24 hours treatment of U266 cell line with these peptides، t he half maximal inhibitory concentration (IC50 %) was obtained 350. 2 and 199. 5 nM for peptide one and two، respectively. With regards to the results، it seems that TRK B inhibition can block cancer growth in this cell line.